Theratechnologies Inc (THERF) 2.3700 $THERF The
Post# of 273254
Posted On: 06/09/2016 2:09:01 AM
Theratechnologies Inc (THERF) 2.3700 $THERF
Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
Marketwired - Tue May 24, 6:02AM CDT
MONTREAL, CANADA--(Marketwired - May 24, 2016) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) announces that it has been notified by its partner, TaiMed Biologics, Inc., of the preliminary results for the primary end point of the phase III trial with ibalizumab in patients with multi-drug resistant HIV-1 (TMB-301).
TH.TO: 3.00 (-0.01)
Announcements in Conjunction With Theratechnologies Annual Meeting
Marketwired - Tue May 17, 11:34AM CDT
MONTREAL, QUEBEC--(Marketwired - May 17, 2016) - Theratechnologies Inc. (TSX:TH) today held its annual meeting of shareholders for the 2015 fiscal year. It was chaired by Dawn Svoronos, chair of the board of Theratechnologies.
TH.TO: 3.00 (-0.01)
Theratechnologies Inc.: Update on Tesamorelin Marketing Authorization Application in Brazil
Marketwire Canada - Mon May 16, 7:55AM CDT
MONTREAL, CANADA--(Marketwired - May 16, 2016) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) announced that its commercial partner, Sanofi, along with Theratechnologies, have decided to withdraw the marketing authorization application for the registration of the 2 mg/vial presentation of tesamorelin in Brazil.
TH.TO: 3.00 (-0.01)
Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial
Marketwired - Wed Apr 27, 7:00PM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has been notified by its partner, TaiMed Biologics, Inc., that the enrollment for the Phase III study of ibalizumab, in combination with optimized background regimen (patients' current therapy), for patients infected with multi-drug resistant HIV-1 has been completed as of April 27, 2016. The enrollment in the US has reached 36 patients, exceeding the minimum of 30 patients proposed by the United States Food and Drug Administration (FDA). The last patient enrolled in the study has entered the initial 7-day control period. On Day 7, ibalizumab will be administered and the primary end point will be assessed 7 days after initiation of ibalizumab on Day 14. The study will continue for a total of 24 weeks of treatment with ibalizumab.
TH.TO: 3.00 (-0.01)
Theratechnologies Announces Financial Results for First Quarter of 2016
Marketwired - Thu Mar 31, 6:01AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the first quarter ended February 29, 2016.
TH.TO: 3.00 (-0.01)
Theratechnologies to Announce Financial Results for the First Quarter of 2016
Marketwired - Wed Mar 23, 10:55AM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the first quarter ended February 29, 2016, on Thursday, March 31, 2016, before markets open.
TH.TO: 3.00 (-0.01)
Theratechnologies and TaiMed Biologics Sign Exclusive Marketing and Distribution Agreement for Ibalizumab
Marketwired - Fri Mar 18, 6:01AM CDT
Theratechnologies inc. (TSX: TH) and TaiMed Biologics, Inc. today announced a 12-year collaboration agreement to market and distribute ibalizumab in the United States and in Canada. Ibalizumab is a novel CD4-directed HIV entry-inhibitor and is the first humanized monoclonal antibody in clinical trials for the treatment of HIV.
TH.TO: 3.00 (-0.01)
Theratechnologies Inc.: Mexico Approves the 1mg/vial Presentation of EGRIFTA(R) (tesamorelin for injection)
Marketwired - Tue Mar 08, 11:03AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that COFEPRIS, Mexico's health agency, has approved the 1mg/vial presentation of tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, allowing the commercialization of EGRIFTA(R) in this territory.
TH.TO: 3.00 (-0.01)
Factors Moving Markets - Complementary Research on Breathe Ecig, mCig, BYD and Theratechnologies
ACCESSWIRE - Tue Jan 19, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Breathe Ecig Corp. (OTC: BVAP), mCig Inc. (OTC: MCIG), BYD Co. Ltd. (OTC: BYDDF) and Theratechnologies Inc. (OTC: THERF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Lipodystrophy - Pipeline Review, H2 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Oct 23, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2l5kl7/lipodystrophy) has announced the addition of the "Lipodystrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegerion Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Bolder Biotechnology, Inc. - Theratechnologies Inc. - Zydus Cadila Healthcare Limited Drug Profiles - ALRN-5281 - ARX-328 - BBT-031 - metreleptin - saroglitazar - tesamorelin acetate - volanesorsen sodium For more information visit http://www.researchandmarkets.com/research/2l...odystrophy
AMBX: (), AEGR: 1.60 (-0.08)
Theratechnologies Announces Financial Results for Third Quarter of 2015
Marketwired - Thu Oct 01, 6:01AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2015.
TH.TO: 3.00 (-0.01)
Theratechnologies to Announce Financial Results for the Third Quarter of 2015
Marketwired - Mon Sep 21, 11:41AM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2015, on Thursday, October 1st, 2015, before markets open.
TH.TO: 3.00 (-0.01)
Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
Marketwired - Tue May 24, 6:02AM CDT
MONTREAL, CANADA--(Marketwired - May 24, 2016) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) announces that it has been notified by its partner, TaiMed Biologics, Inc., of the preliminary results for the primary end point of the phase III trial with ibalizumab in patients with multi-drug resistant HIV-1 (TMB-301).
TH.TO: 3.00 (-0.01)
Announcements in Conjunction With Theratechnologies Annual Meeting
Marketwired - Tue May 17, 11:34AM CDT
MONTREAL, QUEBEC--(Marketwired - May 17, 2016) - Theratechnologies Inc. (TSX:TH) today held its annual meeting of shareholders for the 2015 fiscal year. It was chaired by Dawn Svoronos, chair of the board of Theratechnologies.
TH.TO: 3.00 (-0.01)
Theratechnologies Inc.: Update on Tesamorelin Marketing Authorization Application in Brazil
Marketwire Canada - Mon May 16, 7:55AM CDT
MONTREAL, CANADA--(Marketwired - May 16, 2016) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) announced that its commercial partner, Sanofi, along with Theratechnologies, have decided to withdraw the marketing authorization application for the registration of the 2 mg/vial presentation of tesamorelin in Brazil.
TH.TO: 3.00 (-0.01)
Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial
Marketwired - Wed Apr 27, 7:00PM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has been notified by its partner, TaiMed Biologics, Inc., that the enrollment for the Phase III study of ibalizumab, in combination with optimized background regimen (patients' current therapy), for patients infected with multi-drug resistant HIV-1 has been completed as of April 27, 2016. The enrollment in the US has reached 36 patients, exceeding the minimum of 30 patients proposed by the United States Food and Drug Administration (FDA). The last patient enrolled in the study has entered the initial 7-day control period. On Day 7, ibalizumab will be administered and the primary end point will be assessed 7 days after initiation of ibalizumab on Day 14. The study will continue for a total of 24 weeks of treatment with ibalizumab.
TH.TO: 3.00 (-0.01)
Theratechnologies Announces Financial Results for First Quarter of 2016
Marketwired - Thu Mar 31, 6:01AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the first quarter ended February 29, 2016.
TH.TO: 3.00 (-0.01)
Theratechnologies to Announce Financial Results for the First Quarter of 2016
Marketwired - Wed Mar 23, 10:55AM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the first quarter ended February 29, 2016, on Thursday, March 31, 2016, before markets open.
TH.TO: 3.00 (-0.01)
Theratechnologies and TaiMed Biologics Sign Exclusive Marketing and Distribution Agreement for Ibalizumab
Marketwired - Fri Mar 18, 6:01AM CDT
Theratechnologies inc. (TSX: TH) and TaiMed Biologics, Inc. today announced a 12-year collaboration agreement to market and distribute ibalizumab in the United States and in Canada. Ibalizumab is a novel CD4-directed HIV entry-inhibitor and is the first humanized monoclonal antibody in clinical trials for the treatment of HIV.
TH.TO: 3.00 (-0.01)
Theratechnologies Inc.: Mexico Approves the 1mg/vial Presentation of EGRIFTA(R) (tesamorelin for injection)
Marketwired - Tue Mar 08, 11:03AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that COFEPRIS, Mexico's health agency, has approved the 1mg/vial presentation of tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, allowing the commercialization of EGRIFTA(R) in this territory.
TH.TO: 3.00 (-0.01)
Factors Moving Markets - Complementary Research on Breathe Ecig, mCig, BYD and Theratechnologies
ACCESSWIRE - Tue Jan 19, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Breathe Ecig Corp. (OTC: BVAP), mCig Inc. (OTC: MCIG), BYD Co. Ltd. (OTC: BYDDF) and Theratechnologies Inc. (OTC: THERF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Lipodystrophy - Pipeline Review, H2 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Oct 23, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2l5kl7/lipodystrophy) has announced the addition of the "Lipodystrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegerion Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Bolder Biotechnology, Inc. - Theratechnologies Inc. - Zydus Cadila Healthcare Limited Drug Profiles - ALRN-5281 - ARX-328 - BBT-031 - metreleptin - saroglitazar - tesamorelin acetate - volanesorsen sodium For more information visit http://www.researchandmarkets.com/research/2l...odystrophy
AMBX: (), AEGR: 1.60 (-0.08)
Theratechnologies Announces Financial Results for Third Quarter of 2015
Marketwired - Thu Oct 01, 6:01AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2015.
TH.TO: 3.00 (-0.01)
Theratechnologies to Announce Financial Results for the Third Quarter of 2015
Marketwired - Mon Sep 21, 11:41AM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2015, on Thursday, October 1st, 2015, before markets open.
TH.TO: 3.00 (-0.01)
(0)
(0)Scroll down for more posts ▼